Premium Reports
Contact KLAS
 Download Report Brief  Download Full Report    Zoom in charts



Related Series

Oncology 2023
Oncology 2020
Oncology 2016
Oncology 2014
Oncology 2013
Oncology 2012
Oncology IS 2011
Oncology 2008

 End chart zoom
The Oncology IT Balancing Act The Oncology IT Balancing Act
* A page refresh may be necessary to see the updated image

The Oncology IT Balancing Act
Integration vs. Functionality

September 16, 2010

Where are the oncology offerings from the enterprise vendors? One departmental executive answered, “I just don’t think that a lot of vendors that cover everything have really dialed in on oncology.” Another respondent concurred, “There is such a small group of vendors who offer oncology software.” If providers are looking to purchase an oncology solution that has proven functionality with a significant inpatient and outpatient client base, there are only three vendors that can deliver on these criteria today: Elekta, IntrinsiQ, and Varian. These three vendors make up the bulk of the market. Yet, a group of “up-and-coming” solutions are starting to gain mind and market share, including BMSi, US Oncology, and Altos Solutions.

How do these oncology vendors perform for their clients? Are early adopters moving onto newer solutions? Where are the enterprise vendors in the development of oncology software? KLAS interviewed 137 healthcare provider organizations to answer these questions and to provide a status update on the oncology market.

 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2024 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.